URGN - CIK 0001668243
UroGen Pharma Ltd. (URGN) reported net income of -$153.49M for fiscal year 2025, as filed in its audited annual report with the SEC.
| Fiscal year | Net Income | Change |
|---|---|---|
| FY 2025 | -$153.49M | -21.0% |
| FY 2024 | -$126.87M | -24.1% |
| FY 2023 | -$102.24M | +6.9% |
| FY 2022 | -$109.78M | +0.9% |
| FY 2021 | -$110.82M | +13.7% |
| FY 2020 | -$128.48M | -22.2% |
| FY 2019 | -$105.15M | -39.0% |
| FY 2018 | -$75.66M | -278.3% |
| FY 2017 |
UroGen Pharma Ltd. (URGN) reported net income of -$153.49M for fiscal year 2025, as filed in its audited annual report with the SEC.
Between fiscal 2015 and fiscal 2025, UroGen Pharma Ltd.'s net income declined from -$12.69M to -$153.49M.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| -$20.00M |
| -930.4% |
| FY 2016 | -$1.94M | +84.7% |
| FY 2015 | -$12.69M | - |